AtriCure price target raised to $36 from $32 at Oppenheimer

Oppenheimer raised the firm’s price target on AtriCure (ATRC) to $36 from $32 and keeps an Outperform rating on the shares. The firm notes AtriCure’s Q3 revenues were $116M, slightly above our/consensus $113/$112M estimates. Oppenheimer remains tactically constructive seeing favorable risk/reward as AtriCure trades at about 2.7-times FY25 sales vs. its small-cap MedTech group at about 3.7-times.